On August 20, WUXI XDC rose 4.04% at open, trading at 70.8 HKD/share, with turnover of HKD 4.779 million.

On the news front, the company recently announced that its Singapore-based BCM3 dual-function production line for antibody intermediates and drug substance has successfully completed GMP release. This milestone marks a new stage in the company's global capacity expansion, with BCM3 set to work in synergy with the Wuxi-based BCM1 and BCM2 lines to achieve a substantial leap in production capacity. The formulation line DP4 is also expected to complete GMP release by end of August.

Additionally, the company's board is scheduled to meet on August 24 to review interim results for the first half of the year. Sister company WuXi AppTec reported H1 revenue growth of 38.93% YoY and net profit growth of 29.43%, while raising full-year guidance across the board, bolstering sector-wide expectations. Institutional activity also remains supportive, with Schroders PLC having raised its long position to 5.01% earlier this month.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)